Dacogen administration experience for treatment of patients with myelodisplastic syndrome and chronic myelomonocytic leukemia

S. V. Gritzaev; Грицаев С. В.; K. M. Abdulkadirov; Абдулкадыров К. М.; D. I. Shikhbabaeva; Шихбабаева Д. И.; I. S. Martinkevich; Мартынкевич И. С.; S. A. Tiranova; Тиранова С. А.

doi:10.17650/1818-8346-2009-0-2-28-34

Dacogen administration experience for treatment of patients with myelodisplastic syndrome and chronic myelomonocytic leukemia

Authors: Gritzaev S.V.¹, Abdulkadirov K.M.¹, Shikhbabaeva D.I.¹, Martinkevich I.S.¹, Tiranova S.A.¹
Affiliations:
1. Russian Research Institute of Hematology and Transfusiology
Issue: No 2 (2009)
Pages: 28-34
Section: HEMATOLOGIC MALIGNANCIES: TREATMENT, SUPPORTIVE CARE
Published: 27.05.2009
URL: https://oncohematology.abvpress.ru/ongm/article/view/737
DOI: https://doi.org/10.17650/1818-8346-2009-0-2-28-34
ID: 737

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Dacogen treatment results of 8 MDS patients and 2 CMML patients (a course dose — 100 mg/m2) are presented. Hematological response according to modified IWG criteria (complete remission - 2 pts, bone marrow remission — 1 pts, disease stabilization — 4 pts) has been established in 70% of patients. Complete cytogenetic response has been achieved in one patient with secondary MDS and multiple chromosomal aberrations after 2 therapy courses. Complications because of which intercourse intervals elongated are registered in 3 patients. The obtained data demonstrated efficacy of Dacogen treatment for high risk MDS and CMML patients.